Assertio Holdings Inc
NASDAQ:ASRT
Intrinsic Value
Assertio Holdings, Inc. engages in the provision of commercial pharmaceutical products. [ Read More ]
The intrinsic value of one ASRT stock under the Base Case scenario is 1.26 USD. Compared to the current market price of 0.79 USD, Assertio Holdings Inc is Undervalued by 37%.
Valuation Backtest
Assertio Holdings Inc
Run backtest to discover the historical profit from buying and selling ASRT stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Assertio Holdings Inc
Current Assets | 171.1m |
Cash & Short-Term Investments | 73.4m |
Receivables | 47.7m |
Other Current Assets | 50m |
Non-Current Assets | 115.4m |
PP&E | 2m |
Intangibles | 111.3m |
Other Non-Current Assets | 2m |
Current Liabilities | 93.4m |
Accounts Payable | 13.4m |
Accrued Liabilities | 77.3m |
Other Current Liabilities | 2.7m |
Non-Current Liabilities | 55m |
Long-Term Debt | 38.5m |
Other Non-Current Liabilities | 16.5m |
Earnings Waterfall
Assertio Holdings Inc
Revenue
|
152.1m
USD
|
Cost of Revenue
|
-27m
USD
|
Gross Profit
|
125m
USD
|
Operating Expenses
|
-109m
USD
|
Operating Income
|
16m
USD
|
Other Expenses
|
-348m
USD
|
Net Income
|
-331.9m
USD
|
Free Cash Flow Analysis
Assertio Holdings Inc
ASRT Profitability Score
Profitability Due Diligence
Assertio Holdings Inc's profitability score is 47/100. The higher the profitability score, the more profitable the company is.
Score
Assertio Holdings Inc's profitability score is 47/100. The higher the profitability score, the more profitable the company is.
ASRT Solvency Score
Solvency Due Diligence
Assertio Holdings Inc's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Score
Assertio Holdings Inc's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ASRT Price Targets Summary
Assertio Holdings Inc
According to Wall Street analysts, the average 1-year price target for ASRT is 3.06 USD with a low forecast of 3.03 USD and a high forecast of 3.15 USD.
Ownership
ASRT Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
ASRT Price
Assertio Holdings Inc
Average Annual Return | -6.62% |
Standard Deviation of Annual Returns | 70.1% |
Max Drawdown | -96% |
Market Capitalization | 74.8m USD |
Shares Outstanding | 95 000 000 |
Percentage of Shares Shorted | 11.05% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Assertio Holdings, Inc. engages in the provision of commercial pharmaceutical products. The company is headquartered in Lake Forest, Illinois and currently employs 19 full-time employees. The firm's primary marketed products are INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, INDOCIN (indomethacin) Oral Suspension, CAMBIA (diclofenac potassium for oral solution), Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray and Zipsor (diclofenac potassium) Liquid filled capsules. The firm has other commercially available products, which include OXAYDO (oxycodone HCI, USP) tablets for oral use only. Assertio and Zyla are the registered trademarks of the Company. INDOCIN products are used for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease, moderate to severe ankylosing spondylitis, moderate to severe osteoarthritis, acute painful shoulder (bursitis and/or tendinitis) and acute gouty arthritis.
Contact
IPO
Employees
Officers
The intrinsic value of one ASRT stock under the Base Case scenario is 1.26 USD.
Compared to the current market price of 0.79 USD, Assertio Holdings Inc is Undervalued by 37%.